Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.66 USD | -3.08% | -8.27% | +26.91% |
Financials (USD)
Sales 2024 * | 66.3M | Sales 2025 * | 78.82M | Capitalization | 877M |
---|---|---|---|---|---|
Net income 2024 * | -157M | Net income 2025 * | -124M | EV / Sales 2024 * | 13.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.1 x |
P/E ratio 2024 * |
-5.1
x | P/E ratio 2025 * |
-6.78
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on Ocular Therapeutix, Inc.
1 day | -3.08% | ||
1 week | -8.27% | ||
Current month | +19.41% | ||
1 month | -28.45% | ||
3 months | -0.35% | ||
6 months | +168.88% | ||
Current year | +26.91% |
Managers | Title | Age | Since |
---|---|---|---|
Donald Notman
DFI | Director of Finance/CFO | 64 | 17-09-24 |
Chief Tech/Sci/R&D Officer | - | 21-09-27 | |
Rabia Ozden
CTO | Chief Tech/Sci/R&D Officer | 56 | 21-01-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Adrienne Graves
BRD | Director/Board Member | 69 | 23-07-09 |
Director/Board Member | 76 | 12-11-04 | |
Merilee Raines
BRD | Director/Board Member | 68 | 21-09-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +9.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 5.66 | -3.08% | 2,175,270 |
24-05-09 | 5.84 | +1.57% | 1,718,298 |
24-05-08 | 5.75 | -3.04% | 2,676,953 |
24-05-07 | 5.93 | +2.24% | 2,436,694 |
24-05-06 | 5.8 | -6.00% | 5,676,152 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.91% | 877M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- OCUL Stock